Data Management

Insights identify opportunities to optimize sponsor, CRO, and site collaborations.

The conundrum of missing data vs. inter-rater variability.

Phase III CheckMate -8HW trial shows the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improved progression-free survival and overall response rates in patients with microsatellite-instability–high or mismatch-repair–deficient metastatic colorectal cancer.

Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and monitoring, which could improve patient access and enhance the efficiency of clinical research.

An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab emtansine) significantly improves overall survival and long-term invasive disease–free survival compared to trastuzumab monotherapy in patients with HER2-positive early breast cancer with residual invasive disease.

A focus on data and process excellence advances product development.

Pilot trial shows that a user-friendly electronic patient-reported outcome (ePRO) monitoring system significantly improves patient-centered cardiovascular care by enhancing patient-physician communication, increasing clarity in treatment explanations, and empowering patients with better knowledge of their conditions.

In this video interview, Sujay Jadhav, CEO of Verana Health, talks external control arms and how they can increase study feasibility and inclusivity.

In this video interview, Sujay Jadhav, CEO of Verana Health, highlights the role of real-world evidence alongside unstructured and structured data in better understanding the patient journey.

In this video interview, Sujay Jadhav, CEO of Verana Health, discusses how using genomic data and real-world evidence can provide added context to traditional factors such as Gleason scores and PSA levels.

In this video interview, Sujay Jadhav, CEO of Verana Health, talks AI and its role in optimizing trial design.

Unlocking the full potential of artificial intelligence requires these stakeholders to ensure their data are accessible and secure.

In this video interview, Sujay Jadhav, CEO of Verana Health, highlights how the industry can use RWD to compare outcomes from treatment and non-treatment arms.

In this video interview, Sujay Jadhav, CEO of Verana Health, discusses how the use of unstructured data can help improve clinical research in 2025.

In this video interview, Rachael Fones, director, government & public affairs, IQVIA, highlights the use of real-world data in setting population goals.

Recent analysis showed 81% of clinical trial sites using RBQM statistical data monitoring experienced an improvement in quality.

The three areas poised for a transformation in the advent of electronic clinical outcome assessment technologies.

Use cases spotlight the growing potential of generative AI in the CRO space.

A well-designed approach can benefit clinical trials from protocol design to site support.

Experts weigh in on efforts to realize incremental gains in using AI to ease systemic ills, such as speeding up study enrollment and reducing the risk for unusable flawed data.

A review of industry methods and adoption trends in those trial segments.

The emergence of AI-powered simulants in improving study efficiency.

Mick Ryan, vice president of IT at ICON plc, discusses the growing use of artificial intelligence in clinical research—from technology and data analysis to patient privacy and ethics.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, talks secure data transfer and risk mitigation.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, touches on the challenges with hand-written data collection and how they can be addressed with AI.